M&A
Argenx acquires Unnatural Products for up to $1.15B to expand oral peptide capabilities
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
argenx, Unnatural Products, Merck & Co., Novartis, Forte Biosciences
Date
Argenx (Amsterdam, NL) has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, including $550 million upfront plus development and regulatory milestones. The deal brings UNP's macrocyclic peptide discovery platform and its 50+ person team in Santa Cruz, California, in-house as argenx's peptide hub. UNP had previously partnered with Merck & Co. (2024), argenx (2025), and Novartis (2026).
Argenx's Santa Cruz site becomes its macrocyclic peptide discovery hub, retaining UNP's team and platform. The acquisition expands argenx's capabilities beyond its traditional antibody focus, best known for Vyvgart (anti-FcRn antibody fragment). Argenx continues active business development after its $2.2 billion Forte Biosciences deal in July 2026, which added an anti-CD122 antibody (FB102) for vitiligo and celiac disease.
The deal follows industry trends in oral peptide delivery, as demonstrated by Johnson & Johnson's Icotyde and Merck's Lipfendra, and Gilead's $1.28 billion acquisition of PepStar Therapeutics' oral IL-23 inhibitor. Argenx's acquisition signals continued investment in oral peptide modalities and platform-based M&A.
Post-close integration of UNP's platform and team into argenx's operations, including potential vendor engagements for lab informatics, peptide synthesis, and facility build-out. Argenx's continued BD activity following the Forte Biosciences deal suggests ongoing integration needs across multiple acquisitions.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
